RQ Bio raised an oversubscribed $115 million Series A to advance its long-acting antibody prophylaxis program for seasonal influenza. The financing is intended to move RQB-01 toward IND-enabling work and later clinical evaluation in high-risk and immunocompromised populations, where vaccine protection is often insufficient. The company’s core concept is that a single administration could provide season-long protection through a dual mechanism targeting conserved influenza epitopes. RQB-01 is currently in IND-enabling studies, and the Series A proceeds also support broader prophylactic development across respiratory viral diseases. Lead investors include EQT Life Sciences, and management said the company’s disclosures remain limited beyond the press release level at this stage—suggesting further program specifics may follow as clinical timelines firm up.